Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(5 years from now) | |
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(7 years from now) | |
US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(6 years from now) | |
US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 10, 2024 |
Market Authorisation Date: 04 May, 2017
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based the...
Dosage: TABLET;ORAL
25
United States
10
Australia
9
China
9
Japan
8
Korea, Republic of
7
Argentina
7
European Union
5
Brazil
4
Canada
4
New Zealand
4
Peru
4
Chile
4
Taiwan
4
Mexico
4
Ecuador
4
Tunisia
3
Uruguay
3
Spain
3
Malaysia
3
Singapore
3
Morocco
3
EA
3
Israel
3
Jordan
3
Colombia
2
Poland
2
Ukraine
2
Norway
2
ME
2
Honduras
2
San Marino
2
Croatia
2
Guatemala
2
Portugal
2
Georgia
2
Cuba
2
Costa Rica
2
South Africa
1
IB
1
Hong Kong
1
Dominican Republic
1
Philippines
1
Denmark
1
RS
1
Russia
1
Nicaragua
1
Cyprus
1
Netherlands
1
Lithuania
1
Luxembourg
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic